{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:05:49Z","timestamp":1764605149018,"version":"3.46.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01890-9","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:23:14Z","timestamp":1764598994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phenotypic variability in early-onset dementia segregating with a novel APP (p.I718M) variant"],"prefix":"10.1186","volume":"17","author":[{"given":"Charlotte","family":"Johansson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Rodriguez-Vieitez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Bluma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inger","family":"Nennesmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e5kan","family":"Thonberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbe","family":"Ullgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesna","family":"Jelic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agneta","family":"Nordberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Graff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"10","key":"1890_CR1","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1093\/brain\/awac181","volume":"145","author":"JC Morris","year":"2022","unstructured":"Morris JC, Weiner M, Xiong C, Beckett L, Coble D, Saito N, et al. Autosomal dominant and sporadic late onset Alzheimer\u2019s disease share a common in vivo pathophysiology. Brain. 2022;145(10):3594\u2013607.","journal-title":"Brain"},{"issue":"3","key":"1890_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/jnen\/nlv028","volume":"75","author":"JM Ringman","year":"2016","unstructured":"Ringman JM, Monsell S, Ng DW, Zhou Y, Nguyen A, Coppola G, et al. Neuropathology of autosomal dominant Alzheimer disease in the National Alzheimer coordinating center database. J Neuropathol Exp Neurol. 2016;75(3):284\u201390.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"1890_CR3","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ng0892-345","volume":"1","author":"M Mullan","year":"1992","unstructured":"Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, et al. A pathogenic mutation for probable Alzheimer\u2019s disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1992;1(5):345\u20137.","journal-title":"Nat Genet"},{"issue":"25","key":"1890_CR4","doi-asserted-by":"publisher","first-page":"11993","DOI":"10.1073\/pnas.91.25.11993","volume":"91","author":"M Citron","year":"1994","unstructured":"Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J, et al. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish Familial alzheimer disease mutation. Proc Natl Acad Sci U S A. 1994;91(25):11993\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1890_CR5","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to Familial alzheimer\u2019s disease. Nat Med. 1996;2(8):864\u201370.","journal-title":"Nat Med"},{"issue":"9","key":"1890_CR6","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nn0901-887","volume":"4","author":"C Nilsberth","year":"2001","unstructured":"Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, et al. The \u2018Arctic\u2019 APP mutation (E693G) causes alzheimer\u2019s disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001;4(9):887\u201393.","journal-title":"Nat Neurosci"},{"key":"1890_CR7","first-page":"606","volume":"13","author":"M de la Pagnon","year":"2021","unstructured":"de la Pagnon M, Giedraitis V, Michno W, Kilander L, Guner G, Zielinski M, et al. The Uppsala APP deletion causes early onset autosomal dominant alzheimer\u2019s disease by altering APP processing and increasing amyloid beta fibril formation. Sci Transl Med. 2021;13:606.","journal-title":"Sci Transl Med"},{"issue":"10","key":"1890_CR8","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1038\/emboj.2012.79","volume":"31","author":"L Chavez-Gutierrez","year":"2012","unstructured":"Chavez-Gutierrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M, Borgers M, et al. The mechanism of gamma-Secretase dysfunction in Familial alzheimer disease. EMBO J. 2012;31(10):2261\u201374.","journal-title":"EMBO J"},{"issue":"41","key":"1890_CR9","doi-asserted-by":"publisher","first-page":"13042","DOI":"10.1523\/JNEUROSCI.2362-09.2009","volume":"29","author":"M Takami","year":"2009","unstructured":"Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, et al. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci. 2009;29(41):13042\u201352.","journal-title":"J Neurosci"},{"issue":"2","key":"1890_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/ng1095-219","volume":"11","author":"Alzheimer\u2019s Disease Collaborative G","year":"1995","unstructured":"Alzheimer\u2019s Disease Collaborative G. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nat Genet. 1995;11(2):219\u201322.","journal-title":"Nat Genet"},{"issue":"4","key":"1890_CR11","doi-asserted-by":"publisher","first-page":"E476","DOI":"10.1073\/pnas.1618657114","volume":"114","author":"LF Sun","year":"2017","unstructured":"Sun LF, Zhou R, Yang GH, Shi YG. Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A beta 42 and A beta 40 peptides by gamma-secretase. P Natl Acad Sci USA. 2017;114(4):E476-85.","journal-title":"P Natl Acad Sci USA"},{"issue":"5028","key":"1890_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.1925564","volume":"254","author":"J Murrell","year":"1991","unstructured":"Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated with hereditary Alzheimer\u2019s disease. Science. 1991;254(5028):97\u20139.","journal-title":"Science"},{"issue":"6311","key":"1890_CR13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/349704a0","volume":"349","author":"A Goate","year":"1991","unstructured":"Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature. 1991;349(6311):704\u20136.","journal-title":"Nature"},{"issue":"13","key":"1890_CR14","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/S1474-4422(16)30193-4","volume":"15","author":"NS Ryan","year":"2016","unstructured":"Ryan NS, Nicholas JM, Weston PSJ, Liang Y, Lashley T, Guerreiro R, et al. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer\u2019s disease: a case series. Lancet Neurol. 2016;15(13):1326\u201335.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1890_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1212\/WNL.0000000000000596","volume":"83","author":"DC Ryman","year":"2014","unstructured":"Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83(3):253\u201360.","journal-title":"Neurology"},{"issue":"5","key":"1890_CR16","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1212\/NXG.0000000000000507","volume":"6","author":"IM Pavisic","year":"2020","unstructured":"Pavisic IM, Nicholas JM, O\u2019Connor A, Rice H, Lu K, Fox NC, et al. Disease duration in autosomal dominant Familial alzheimer disease: A survival analysis. Neurol Genet. 2020;6(5):e507.","journal-title":"Neurol Genet"},{"issue":"13","key":"1890_CR17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1474-4422(16)30229-0","volume":"15","author":"M Tang","year":"2016","unstructured":"Tang M, Ryman DC, McDade E, Jasielec MS, Buckles VD, Cairns NJ, et al. Neurological manifestations of autosomal dominant Familial alzheimer\u2019s disease: a comparison of the published literature with the dominantly inherited alzheimer network observational study (DIAN-OBS). Lancet Neurol. 2016;15(13):1317\u201325.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1890_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3233\/JAD-170031","volume":"60","author":"AJ Beagle","year":"2017","unstructured":"Beagle AJ, Darwish SM, Ranasinghe KG, La AL, Karageorgiou E, Vossel KA. Relative incidence of seizures and myoclonus in Alzheimer\u2019s disease, dementia with Lewy bodies, and frontotemporal dementia. J Alzheimers Dis. 2017;60(1):211\u201323.","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"1890_CR19","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer\u2019s disease. Neurology. 1984;34(7):939\u201344.","journal-title":"Neurology"},{"issue":"3","key":"1890_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1890_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology"},{"issue":"8","key":"1890_CR22","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/archneur.65.8.1091","volume":"65","author":"SE O\u2019Bryant","year":"2008","unstructured":"O\u2019Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, et al. Staging dementia using clinical dementia rating scale sum of boxes scores: a Texas alzheimer\u2019s research consortium study. Arch Neurol. 2008;65(8):1091\u20135.","journal-title":"Arch Neurol"},{"issue":"3","key":"1890_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398.","journal-title":"J Psychiatr Res"},{"issue":"2","key":"1890_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/jhg.2016.108","volume":"62","author":"HH Chiang","year":"2017","unstructured":"Chiang HH, Forsell C, Lindstrom AK, Lilius L, Thonberg H, Nennesmo I, et al. No common founder for C9orf72 expansion mutation in Sweden. J Hum Genet. 2017;62(2):321\u20134.","journal-title":"J Hum Genet"},{"issue":"Pt 11","key":"1890_CR25","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1093\/brain\/awl178","volume":"129","author":"H Engler","year":"2006","unstructured":"Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer\u2019s disease. Brain. 2006;129(Pt 11):2856\u201366.","journal-title":"Brain"},{"issue":"3","key":"1890_CR26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306\u201319.","journal-title":"Ann Neurol"},{"issue":"6","key":"1890_CR27","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1007\/s00259-019-04297-5","volume":"46","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Savitcheva I, Chiotis K, Lilja J, Andersen P, Bogdanovic N, et al. Clinical impact of [(18)F]flutemetamol PET among memory clinic patients with an unclear diagnosis. Eur J Nucl Med Mol Imaging. 2019;46(6):1276\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1890_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.118775","volume":"246","author":"L Iaccarino","year":"2022","unstructured":"Iaccarino L, La Joie R, Koeppe R, Siegel BA, Hillner BE, Gatsonis C, et al. rPOP: robust PET-only processing of community acquired heterogeneous amyloid-PET data. Neuroimage. 2022;246:118775.","journal-title":"Neuroimage"},{"issue":"1","key":"1890_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Sr., Jagust WJ, et al. The centiloid project: standardizing quantitative amyloid plaque Estimation by PET. Alzheimers Dement. 2015;11(1):1\u2013e151.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1890_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-018-0456-7","volume":"8","author":"MR Battle","year":"2018","unstructured":"Battle MR, Pillay LC, Lowe VJ, Knopman D, Kemp B, Rowe CC, et al. Centiloid scaling for quantification of brain amyloid with [(18)F]flutemetamol using multiple processing methods. EJNMMI Res. 2018;8(1):107.","journal-title":"EJNMMI Res"},{"issue":"12","key":"1890_CR31","doi-asserted-by":"publisher","first-page":"9037","DOI":"10.1002\/alz.14336","volume":"20","author":"LE Collij","year":"2024","unstructured":"Collij LE, Bollack A, La Joie R, Shekari M, Bullich S, Roe-Vellve N, et al. Centiloid recommendations for clinical context-of-use from the AMYPAD consortium. Alzheimers Dement. 2024;20(12):9037\u201348.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"1890_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100008","volume":"12","author":"G Farrar","year":"2025","unstructured":"Farrar G, Weber CJ, Rabinovici GD. Expert opinion on centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer\u2019s Association research roundtable. J Prev Alzheimers Dis. 2025;12(1):100008.","journal-title":"J Prev Alzheimers Dis"},{"issue":"9","key":"1890_CR33","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/BF00868807","volume":"242","author":"P Scheltens","year":"1995","unstructured":"Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol. 1995;242(9):557\u201360.","journal-title":"J Neurol"},{"issue":"5","key":"1890_CR34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000117270","volume":"36","author":"F Pasquier","year":"1996","unstructured":"Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P. Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol. 1996;36(5):268\u201372.","journal-title":"Eur Neurol"},{"issue":"2","key":"1890_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351\u20136.","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"1890_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National institute on aging-Alzheimer\u2019s association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 2012;8(1):1\u201313.","journal-title":"Alzheimers Dement"},{"issue":"s1","key":"1890_CR37","doi-asserted-by":"publisher","first-page":"S491","DOI":"10.3233\/JAD-179922","volume":"64","author":"S Thordardottir","year":"2018","unstructured":"Thordardottir S, Graff C. Findings from the Swedish study on familial alzheimer\u2019s disease including the APP Swedish double mutation. J Alzheimers Dis. 2018;64(s1):S491-6.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1890_CR38","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3233\/JAD-191261","volume":"76","author":"S Thordardottir","year":"2020","unstructured":"Thordardottir S, Almkvist O, Johansson C, Zetterberg H, Blennow K, Graff C. Cerebrospinal fluid YKL-40 and neurogranin in familial Alzheimer\u2019s disease: a pilot study. J Alzheimers Dis. 2020;76(3):941\u201353.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"1890_CR39","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/brain\/awac399","volume":"146","author":"C Johansson","year":"2023","unstructured":"Johansson C, Thordardottir S, Laffita-Mesa J, Rodriguez-Vieitez E, Zetterberg H, Blennow K, et al. Plasma biomarker profiles in autosomal dominant Alzheimer\u2019s disease. Brain. 2023;146(3):1132\u201340.","journal-title":"Brain"},{"issue":"5","key":"1890_CR40","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated Tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1890_CR41","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/alz.13525","volume":"20","author":"F Gonzalez-Ortiz","year":"2024","unstructured":"Gonzalez-Ortiz F, Ferreira PCL, Gonzalez-Escalante A, Montoliu-Gaya L, Ortiz-Romero P, Kac PR, et al. A novel ultrasensitive assay for plasma p-tau217: performance in individuals with subjective cognitive decline and early alzheimer\u2019s disease. Alzheimers Dement. 2024;20(2):1239\u201349.","journal-title":"Alzheimers Dement"},{"key":"1890_CR42","doi-asserted-by":"crossref","unstructured":"Johansson C. The Alzheimer disease continuum - findings from monogenic Alzheimer disease. Stockholm: Karolinska Institutet; 2025.\u00a0https:\/\/openarchive-kise.proxy.kib.ki.se\/articles\/thesis\/The_Alzheimer_disease_continuum_findings_from_monogenic_Alzheimer_disease\/28639856?file=53747933.","DOI":"10.69622\/28639856"},{"key":"1890_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41531-019-0097-1","volume":"5","author":"R Balestrino","year":"2019","unstructured":"Balestrino R, Hurtado-Gonzalez CA, Stocchi F, Radicati FG, Chaudhuri KR, Rodriguez-Blazquez C, et al. Applications of the European parkinson\u2019s disease association sponsored parkinson\u2019s disease composite scale (PDCS). NPJ Parkinsons Dis. 2019;5:26.","journal-title":"NPJ Parkinsons Dis"},{"issue":"3","key":"1890_CR44","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/joim.12358","volume":"278","author":"D Ferreira","year":"2015","unstructured":"Ferreira D, Cavallin L, Larsson EM, Muehlboeck JS, Mecocci P, Vellas B, et al. Practical cut-offs for visual rating scales of medial temporal, frontal and posterior atrophy in alzheimer\u2019s disease and mild cognitive impairment. J Intern Med. 2015;278(3):277\u201390.","journal-title":"J Intern Med"},{"issue":"5","key":"1890_CR45","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"issue":"8","key":"1890_CR46","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimers Dement. 2024;20(8):5143\u201369.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"1890_CR47","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr.","year":"2016","unstructured":"Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A\/T\/N: an unbiased descriptive classification scheme for alzheimer disease biomarkers. Neurology. 2016;87(5):539\u201347.","journal-title":"Neurology"},{"issue":"Pt 4","key":"1890_CR48","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/brain\/awq033","volume":"133","author":"S Jayadev","year":"2010","unstructured":"Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu CE, et al. Alzheimer\u2019s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain. 2010;133(Pt 4):1143\u201354.","journal-title":"Brain"},{"key":"1890_CR49","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jns.2016.10.039","volume":"372","author":"G Zhang","year":"2017","unstructured":"Zhang G, Xie Y, Wang W, Feng X, Jia J. Clinical characterization of an APP mutation (V717I) in five Han Chinese families with early-onset Alzheimer\u2019s disease. J Neurol Sci. 2017;372:379\u201386.","journal-title":"J Neurol Sci"},{"issue":"11","key":"1890_CR50","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","volume":"25","author":"JF Arboleda-Velasquez","year":"2019","unstructured":"Arboleda-Velasquez JF, Lopera F, O\u2019Hare M, Delgado-Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25(11):1680\u20133.","journal-title":"Nat Med"},{"issue":"1","key":"1890_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0374-y","volume":"10","author":"S Thordardottir","year":"2018","unstructured":"Thordardottir S, Rodriguez-Vieitez E, Almkvist O, Ferreira D, Saint-Aubert L, Kinhult-Stahlbom A, et al. Reduced penetrance of the PSEN1 H163Y autosomal dominant alzheimer mutation: a 22-year follow-up study. Alzheimers Res Ther. 2018;10(1):45.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"1890_CR52","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/ana.10636","volume":"54","author":"P Pastor","year":"2003","unstructured":"Pastor P, Roe CM, Villegas A, Bedoya G, Chakraverty S, Garcia G, et al. Apolipoprotein E epsilon 4 modifies alzheimer\u2019s disease onset in an E280A PS1 kindred. Ann Neurol. 2003;54(2):163\u20139.","journal-title":"Ann Neurol"},{"issue":"7","key":"1890_CR53","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/mp.2015.177","volume":"21","author":"JI Velez","year":"2016","unstructured":"Velez JI, Lopera F, Sepulveda-Falla D, Patel HR, Johar AS, Chuah A, et al. APOE*E2 allele delays age of onset in PSEN1 E280A alzheimer\u2019s disease. Mol Psychiatry. 2016;21(7):916\u201324.","journal-title":"Mol Psychiatry"},{"key":"1890_CR54","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1192\/bjp.176.5.468","volume":"176","author":"S Deb","year":"2000","unstructured":"Deb S, Braganza J, Norton N, Williams H, Kehoe PG, Williams J, et al. APOE epsilon 4 influences the manifestation of alzheimer\u2019s disease in adults with down\u2019s syndrome. Br J Psychiatry. 2000;176:468\u201372.","journal-title":"Br J Psychiatry"},{"issue":"11","key":"1890_CR55","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/gps.2039","volume":"23","author":"VP Prasher","year":"2008","unstructured":"Prasher VP, Sajith SG, Rees SD, Patel A, Tewari S, Schupf N, et al. Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer\u2019s disease and mortality in persons with Down syndrome. Int J Geriatr Psychiatry. 2008;23(11):1134\u201340.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"4","key":"1890_CR56","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/neup.12205","volume":"35","author":"NJ Cairns","year":"2015","unstructured":"Cairns NJ, Perrin RJ, Franklin EE, Carter D, Vincent B, Xie M, et al. Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). Neuropathology. 2015;35(4):390\u2013400.","journal-title":"Neuropathology"},{"issue":"12","key":"1890_CR57","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith IG, Dickson DW, Lowe J, Emre M, O\u2019Brien JT, Feldman H, et al. Diagnosis and management of dementia with lewy bodies: third report of the DLB consortium. Neurology. 2005;65(12):1863\u201372.","journal-title":"Neurology"},{"issue":"3","key":"1890_CR58","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","volume":"10","author":"RL Hamilton","year":"2000","unstructured":"Hamilton RL. Lewy bodies in Alzheimer\u2019s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000;10(3):378\u201384.","journal-title":"Brain Pathol"},{"issue":"1","key":"1890_CR59","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2217\/bmm.09.92","volume":"4","author":"NS Ryan","year":"2010","unstructured":"Ryan NS, Rossor MN. Correlating familial Alzheimer\u2019s disease gene mutations with clinical phenotype. Biomark Med. 2010;4(1):99\u2013112.","journal-title":"Biomark Med"},{"issue":"2","key":"1890_CR60","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00401-002-0536-6","volume":"104","author":"M Takao","year":"2002","unstructured":"Takao M, Ghetti B, Hayakawa I, Ikeda E, Fukuuchi Y, Miravalle L, et al. A novel mutation (G217D) in the presenilin 1 gene (PSEN1) in a Japanese family: presenile dementia and parkinsonism are associated with cotton wool plaques in the cortex and striatum. Acta Neuropathol. 2002;104(2):155\u201370.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1890_CR61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3233\/JAD-141524","volume":"44","author":"E Sieczkowski","year":"2015","unstructured":"Sieczkowski E, Milenkovic I, Venkataramani V, Giera R, Strobel T, Hoftberger R, et al. I716F AbetaPP mutation associates with the deposition of oligomeric pyroglutamate amyloid-beta and alpha-synucleinopathy with lewy bodies. J Alzheimers Dis. 2015;44(1):103\u201314.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"1890_CR62","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/WAD.0000000000000206","volume":"31","author":"D Zadori","year":"2017","unstructured":"Zadori D, Fuvesi J, Timar E, Horvath E, Bencsik R, Szepfalusi N, et al. The report of p.Val717Phe mutation in the APP gene in a Hungarian family with Alzheimer disease: a phenomenological study. Alzheimer Dis Assoc Disord. 2017;31(4):343\u20135.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1890_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-38","volume":"12","author":"M Abe","year":"2012","unstructured":"Abe M, Sonobe N, Fukuhara R, Mori Y, Ochi S, Matsumoto T, et al. Phenotypical difference of amyloid precursor protein (APP) V717L mutation in Japanese family. BMC Neurol. 2012;12:38.","journal-title":"BMC Neurol"},{"issue":"2","key":"1890_CR64","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1212\/01.WNL.0000149761.70566.3E","volume":"64","author":"T Edwards-Lee","year":"2005","unstructured":"Edwards-Lee T, Ringman JM, Chung J, Werner J, Morgan A, St George Hyslop P, et al. An African American family with early-onset Alzheimer disease and an APP (T714I) mutation. Neurology. 2005;64(2):377\u20139.","journal-title":"Neurology"},{"issue":"1","key":"1890_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-0891-3","volume":"8","author":"GM Lloyd","year":"2020","unstructured":"Lloyd GM, Trejo-Lopez JA, Xia Y, McFarland KN, Lincoln SJ, Ertekin-Taner N, et al. Prominent amyloid plaque pathology and cerebral amyloid angiopathy in APP V717I (London) carrier - phenotypic variability in autosomal dominant Alzheimer\u2019s disease. Acta Neuropathol Commun. 2020;8(1):31.","journal-title":"Acta Neuropathol Commun"},{"key":"1890_CR66","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/bmb\/66.1.213","volume":"66","author":"P Gambetti","year":"2003","unstructured":"Gambetti P, Kong Q, Zou W, Parchi P, Chen SG. Sporadic and familial CJD: classification and characterisation. Br Med Bull. 2003;66:213\u201339.","journal-title":"Br Med Bull"},{"key":"1890_CR67","doi-asserted-by":"crossref","unstructured":"O\u2019Connor A, Pannee J, Poole T, Arber C, Portelius E, Swift IJ, et al. Plasma amyloid-beta ratios in autosomal dominant Alzheimer\u2019s disease: the influence of genotype. Brain. 2021;144(10):2964\u201370.","DOI":"10.1093\/brain\/awab166"},{"key":"1890_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100281","volume":"296","author":"S Devkota","year":"2021","unstructured":"Devkota S, Williams TD, Wolfe MS. Familial alzheimer\u2019s disease mutations in amyloid protein precursor alter proteolysis by gamma-secretase to increase amyloid beta-peptides of >\/=45 residues. J Biol Chem. 2021;296:100281.","journal-title":"J Biol Chem"},{"issue":"3","key":"1890_CR69","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3):512\u20139.","journal-title":"Ann Neurol"},{"issue":"3","key":"1890_CR70","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/archneurol.2008.596","volume":"66","author":"T Tapiola","year":"2009","unstructured":"Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid {beta}-amyloid 42 and Tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66(3):382\u20139.","journal-title":"Arch Neurol"},{"issue":"14","key":"1890_CR71","doi-asserted-by":"publisher","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","volume":"91","author":"E McDade","year":"2018","unstructured":"McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018;91(14):e1295-306.","journal-title":"Neurology"},{"issue":"3","key":"1890_CR72","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Zetterberg H, Mattsson N, Palmqvist S, Vanderstichele H, Lindberg O, et al. CSF Abeta42\/Abeta40 and Abeta42\/Abeta38 ratios: better diagnostic markers of alzheimer disease. Ann Clin Transl Neurol. 2016;3(3):154\u201365.","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"1890_CR73","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41380-019-0410-8","volume":"25","author":"C Arber","year":"2020","unstructured":"Arber C, Toombs J, Lovejoy C, Ryan NS, Paterson RW, Willumsen N, et al. Familial Alzheimer\u2019s disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Mol Psychiatry. 2020;25(11):2919\u201331.","journal-title":"Mol Psychiatry"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01890-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01890-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01890-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:02:47Z","timestamp":1764604967000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01890-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1890"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01890-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"type":"electronic","value":"1758-9193"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for participation and publication were provided by all participants and the study was conducted in agreement with the Helsinki Declaration. The ethical approvals for collection and analyses in the\n                      APP\n                      p.I718M family, including \u201cGEDOC\u201d (dnr 2011\/1987-31\/4) and the \u201cGenetic and biochemical analysis of human tissue for neurodegenerative disease and their phenotype (AD-registret)\u201d (dnr 2017-834-31-1), were approved by the Regional Ethical Review Board in Stockholm, Sweden. The Swedish Familial Alzheimer Disease (FAD) study was approved by the Regional Ethical Review Board in Stockholm (dnr 2006\/901\u2009\u2212\u200931\/3) and the Swedish Ethical Review Authority (addendum dnr 2022-06565-02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for participation and publication were provided by all participants. An additional written informed consent for detailed case reports presented in the Supplementary Material were obtained from participants themselves or next-of-kin.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CG, CJ, AU, ERV, VJ, HT, IN and MB report no competing interests. AN has received honoraria for lectures from Hoffman-La Roche, Astra Zeneca, consulting fees from Lundbeck AG, AVVA pharmaceuticals and has served in an advisory board for NSN Therapeutics. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD. KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}